Milan, Italy (March 12th, 2020) | Sentinel Diagnostics (www.sentineldiagnostics.com), an Italian Company focused on the development and production of In Vitro Diagnostics for the most advanced Clinical Chemistry, Immunochemistry and Molecular Diagnostics platforms, has announced today that its new assay for the detection of novel Coronavirus disease (COVID-19) is ready. This test has been developed together with the most important hospital lab for the detection and treatment of coronavirus in Italy.
Sentinel Diagnostics has more than 35 years experience in the development and production of IVD products designed for use in medical analysis labs and healthcare structures. In the last 12 years the company has grown in the Molecular Diagnostics sector and has developed the proprietary technology STAT-NAT®, able to stabilize the activity of PCR mix, allowing room temperature transport and storage, performance improvement and long shelf life. STAT-NAT® can be customized for all NAT systems, from POC to central laboratory.
Sentinel Diagnostics’ STAT-NAT® COVID-19 assay is a freeze-dried ready-to-use Real-Time PCR mix for the detection of novel Coronavirus disease (COVID-19) in human respiratory tract specimens in about 90 minutes. The company developed two versions of this kit, which follow two international protocols for the highest sensitivity and specificity. STAT-NAT® COVID-19 HK kit is based on the Hong Kong protocol, while STAT-NAT® COVID-19 B assay follows the Berlin protocol. Both these kits are validated on the most common PCR instruments and have been tested on human respiratory tract specimens found positive.
“The R&D NAT team has developed and tested the COVID-19 assay by working side by side with one of the reference hospital labs for the detection and treatment of coronavirus in Italy” explains Maurizio Gramegna, Chief Technology Officer at Sentinel Diagnostics. “Both STAT-NAT® COVID-19 HK and B are compliant with the international protocols and are able to detect the relevant genetic variants of Coronavirus COVID-19. We are always in touch with KOLs, in order to keep the assays up to date and even update them in case of any virus mutation.”
STAT-NAT® COVID-19 assay isn’t the only news in the offer of the company. Sentinel Diagnostics has just enlarged its Molecular Diagnostics portfolio with a wide number of Real-Time PCR tests. The new assays are available for a wide variety of clinical applications in virology, post-transplant monitoring, hospital acquired infection detection and pharmacogenetics applications.
In the fourth quarter of 2020, Sentinel Diagnostics is also going to launch SENTiNAT®200, a new end-to-end fully automated solution for PCR-based Molecular Diagnostics. SENTiNAT®200 is going to be a flexible, fast, compact robotic workstation to efficiently automate sample preparation and will include two Real Time thermal cyclers to manage all the steps: from sample to the final result. The STAT-NAT® COVID-19 kit, as well as all the on-market STAT-NAT® assays, will be available on this system.
Sentinel Diagnostics (Sentinel CH. SpA) is an Italian company based in Milan, managed by Matteo Roveda and Filippo De Luca, Executive Vice Presidents. The firm is focused on the development and production of In Vitro Diagnostics for the most advanced Clinical Chemistry, Immunochemistry and Molecular Diagnostics platforms. Besides the wide product portfolio in Clinical Chemistry, the FOB Gold® line is Sentinel’s complete solution for colorectal cancer screening, which includes patented sampling devices and analytical systems. In the field of Molecular Biology, the STAT-NAT® portfolio is the company’s answer to the market need for easy, ready to use and eco-friendly Molecular Diagnostics, high in quality and sensitivity. For more information, visitwww.sentineldiagnostics.com.
Head of Marketing
Chief Technology Officer – NAT
Sales Information/ Request a Quote